Vnitr Lek 2015, 61(4):301-303

Biosimilar insulines - new possibilities of diabetes treatment

Jan Škrha
III. interní klinika 1. LF UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA

Biosimilar insulins are biological drugs with the effect similar to reference insulins. Documented safety and efficacy are the main demand for their clinical utility. The subsequent introduction into clinical practice will be followed by more frequent use which will need longterm evaluation of their effect on glycemia and eventual side effects as well.

Keywords: biosimilar insulin; clinical utility; efficacy; reference insulin; safety

Received: February 9, 2015; Accepted: March 13, 2015; Published: April 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Škrha J. Biosimilar insulines - new possibilities of diabetes treatment. Vnitr Lek. 2015;61(4):301-303.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Slíva J. Co jsou a co nám přinášejí biosimilars? Vnitř Lék 2015; 61(2): 143-145. Go to PubMed...
    2. DeVries JH, Gough SCL, Kiljanski J et al. Biosimilar insulins: a European perspective. Diabetes Obes Metab 2014; Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12410>. Go to original source... Go to PubMed...
    3. Edelman S, Polonsky WH, Parkin CG. Biosimilar insulins are coming: what they are, what you need to know? Curr Med Res Opin 2014; 30(11): 2217-2222. Go to original source... Go to PubMed...
    4. Blumer I, Edelman S. Biosimilar insulins are coming: the top 10 things you should know. Postgrad Med 2014; 126(3): 107-110. Go to original source... Go to PubMed...
    5. Owens DR, Landgraf W, Schmidt A et al. The emergence of biosimilar insulin preparations - a cause for concern? Diabetes Technol Ther 2012; 14(11): 989-996. Go to original source... Go to PubMed...
    6. Grzeszczak W, Bijos P, Borkowski M et al. A comparison of the efficacy and safety in patients with type 2 diabetes mellitus managed with premixed human insulin (Gensulin M30) versus pre-mixed insulin aspart 30/70 (NovoMix 30). Diabet Dosw Klin 2010; 10: 53-59.
    7. Verma M, Hazra P, Iyer H et al. Basalog® is similar to Lantus® in producing glycemic control in patients with type 1 diabetes mellitus on multiple daily insulin regimens. Int J Diabetes Dev Ctries 2011; 31(1): 26-31. Go to original source...
    8. Heinemann L, Hompesch M. Biosimilar insulins: how simuilar is similar? J Diabetes Sci Technol 2011; 5(3): 741-754. Go to original source... Go to PubMed...
    9. Gough S. Biosimilar insulins: opportunities and challenges. Practical Diabetes 2013; 30(4): 146-147. Go to original source...
    10. Wilkins AR, Venkat MV, Brown AS et al. Patient perspectives on biosimilar insulin. J Diabetes Sci Technol 2014; 8(1): 23-25. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.